GSK’s Head Of Artificial Intelligence Unveils R&D Goals
Executive Summary
GSK’s John Baldoni talks to Scrip in an exclusive interview about taking over the big pharma’s artificial intelligence R&D strategy and the company’s early-stage progress using machine-driven discovery and development methods.
You may also be interested in...
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.